AbbVieXSWX:ABBV 65 10-Year ROIIC % is 9.50 as of Dec. 2025. GuruFocus rates XSWX:ABBV with a GF Score™ of 65/100 and a GF Value™ of CHF167.66 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 859 Drug Manufacturers companies, AbbVie ranks better than 62.51% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
AbbVie's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 9.50%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for AbbVie's 10-Year ROIIC % or its related term are showing as below:
XSWX:ABBV's 10-Year ROIIC % is ranked better than 62.51% of 859
companies
in the Drug Manufacturers industry
Industry Median: 4.44
vs XSWX:ABBV: 9.50
AbbVie (XSWX:ABBV) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
AbbVie 10-Year ROIIC % Related Terms
AbbVie 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for AbbVie's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ABBV vs MRK, JNJ, AMGN: 10-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, AbbVie's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbbVie 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AbbVie's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where AbbVie's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
AbbVie (XSWX:ABBV) has a 10-Year ROIIC % of 9.50 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on AbbVie and its competitors. According to the industry distribution chart, AbbVie ranks #322 out of 859 companies in the Drug Manufacturers industry, placing it in the top 37.5%.
Is AbbVie's 10-Year ROIIC % too high?
AbbVie's current 10-Year ROIIC % is 9.50. The Drug Manufacturers industry median 10-Year ROIIC % is 4.44. AbbVie's value of 9.50 is 114% above this industry median. Based on the distribution chart, AbbVie ranks #322 out of 859 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, AbbVie has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's 10-Year ROIIC % compare to MRK and JNJ?
According to the Drug Manufacturers industry distribution chart, AbbVie ranks #322 out of 859 companies for 10-Year ROIIC %. This puts AbbVie in the upper half of its industry. The industry median 10-Year ROIIC % is 4.44. AbbVie's value of 9.50 is 114% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.44, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbbVie's current 10-Year ROIIC % of 9.50 is 114% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on AbbVie and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbbVie's current 10-Year ROIIC % is 9.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (XSWX:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF167.66, compared to a current price of CHF206.75 — trading 23.3% above its estimated fair value. The current 10-Year ROIIC % is 9.50 and 114% above the Drug Manufacturers industry median of 4.44. AbbVie's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For AbbVie (XSWX:ABBV), the current 10-Year ROIIC % is 9.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbbVie (XSWX:ABBV) Overvalued in 2026?
Based on GuruFocus' analysis, AbbVie stock appears to be overvalued.
The current stock price of CHF206.75 is trading 23.3% above its estimated GF Value™ of CHF167.66.
GuruFocus considers AbbVie to be Modestly Overvalued.
Key valuation signals for XSWX:ABBV:
10-Year ROIIC %: 9.50
GF Value™: CHF167.66 vs. price of CHF206.75 (23.3% above fair value)
Industry Position: 114% above the Drug Manufacturers median (#322 of 859)
No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score
Get the complete analysis for XSWX:ABBV
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ABBV has been successfully added to your 
